Nothing Special   »   [go: up one dir, main page]

Venero et al., 2002 - Google Patents

DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury

Venero et al., 2002

Document ID
2254830556205070850
Author
Venero J
Santiago M
Tomas-Camardiel M
Matarredona E
Cano J
Machado A
Publication year
Publication venue
Neuroscience

External Links

Snippet

We have previously described a neuroprotective action of (2S, 2′ R, 3′ R)-2-(2′ 3′- dicarboxycyclopropyl) glycine (DCG-IV), an agonist for group-II metabotropic receptors, on dopaminergic nerve terminals against the degeneration induced by 1-methyl-4 …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Venero et al. DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury
Van Den Pol et al. Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus
Prosser et al. A possible glial role in the mammalian circadian clock
Verkhratsky et al. Ion channels in glial cells
Gilad et al. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats
Matarredona et al. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction
Yoshimoto et al. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat
US9180171B2 (en) Method of regulating fertilizing ability using cyclic ADP-ribose and CD38
Edvinsson et al. Pharmacological characterization of GABA receptors mediating vasodilation of cerebral arteries in vitro
Leanza et al. Effects of neonatal lesions of the basal forebrain cholinergic system by 192 immunoglobulin G-saporin: biochemical, behavioural and morphological characterization
Nasehi et al. The effects of dopaminergic drugs in the dorsal hippocampus of mice in the nicotine-induced anxiogenic-like response
Hassanain et al. Potentiating role of interleukin-1β (IL-1β) and IL-1β type 1 receptors in the medial hypothalamus in defensive rage behavior in the cat
Wang et al. Astroglial regulation of magnocellular neuroendocrine cell activities in the supraoptic nucleus
KR20130038286A (en) USE OF 5A-ANDROSTANE (ALKYL)-3β,5,6β-TRIOL IN PREPARATION OF NEUROPROTECTIVE DRUGS
El-Sherif et al. Factors regulating the influence of melatonin on hippocampal evoked potentials: comparative studies on different strains of mice
Li et al. GABAB receptors in the hippocampal dentate gyrus are involved in spatial learning and memory impairment in a rat model of vascular dementia
Cramer et al. The neuronal form of nitric oxide synthase is required for pattern formation by retinal afferents in the ferret lateral geniculate nucleus
Loiacono et al. Hippocampal lesions induced by microinjection of the nitric oxide donor nitroprusside
HERTZ et al. Astrocyte-neuron interaction during one-trial aversive learning in the neonate chick
Takahashi et al. Effects of nicotine and footshock stress on dopamine release in the striatum and nucleus accumbens
Chen et al. Co-localization of NMDA receptors and AMPA receptors in neurons of the vestibular nuclei of rats
Bitar et al. Diabetes-induced changes in monoamine concentrations of rat hypothalamic nuclei
Zhang et al. Treatment with progesterone after focal cerebral ischemia suppresses proliferation of progenitor cells but enhances survival of newborn neurons in adult male mice
Saigusa et al. In vivo neurochemical evidence that newly synthesised GABA activates GABAB, but not GABAA, receptors on dopaminergic nerve endings in the nucleus accumbens of freely moving rats
Rasmussen et al. Strychnine-blocked glycine receptor is removed from synapses by a shift in insertion/degradation equilibrium